ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2023
Role of the Gut Microbiota and Its Metabolites in Tumorigenesis or Development of Colorectal Cancer.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 190 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
190 citing papers in PubMed, 7 syntheses or guidelines pooled it, 238 citations in OpenAlex.
- Salivary microbial meta-analysis reveals gender differences in oral microbiota, core microbiota, and molecular markers.Frontiers in cellular and infection microbiology · 2026Pooled it
- The Role of the Gut Microbiome in Clinical Outcomes of Colorectal Cancer: A Systematic Review (2020-2025).Oncology research · 2026Pooled it
- Pooled it
- Cross-cohort analysis identifies shared gut microbial signatures and validates microbial risk scores for colorectal cancer.Journal of translational medicine · 2025Pooled it
- Systematic review on the role of the gut microbiota in tumors and their treatment.Frontiers in endocrinology · 2024Pooled it
- Bibliometric analysis of research on gut microbiota and bile acids: publication trends and research frontiers.Frontiers in microbiology · 2024Pooled it
- The impact of pre-, pro- and synbiotics supplementation in colorectal cancer treatment: a systematic review.Frontiers in oncology · 2024Pooled it
- Decoding the microbiome: artificial intelligence-targeted gut microenvironment breakthroughs in personalized cancer therapy.Gut microbes · 2026Review
- Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management.MedComm · 2026Review
- Novel inhibitors against Cryptosporidium parvum through blocking its energy metabolism.PLoS neglected tropical diseases · 2026Article
- Association between Clostridium septicum and Streptococcus gallolyticus bacteremia and colorectal neoplasms.Surgery today · 2026Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Fatty Acid Heterogeneity in Colorectal Cancer: From Food Matrices to Targeted Interventions.Cancers · 2026Review
- Intratumoral microbiota in tumorigenesis: A double-edged sword.Chinese medical journal · 2026Review
- Intratumoral microbiota in the growth of CRC and lung cancer: Comprehensive insights from etiology to therapy.iScience · 2026Review
- Integrative Multi-Omics Analysis Reveals Host Regulatory and Immune Networks with Inferred Dysbiosis Relevance in Colorectal Cancer.Journal of clinical medicine · 2026Article
- Intratumoral microbiota in colorectal cancer: roles, therapeutic potential, and challenges.Journal of advanced research · 2026Review
- Microbiota-Mediator-Host Signaling Networks in Metabolic Syndrome: From Mechanistic Insights to Therapeutic Targeting.Microorganisms · 2026Review
- Migration of immune cells in tumors and inflammation: molecular mechanisms and therapeutic targets.Signal transduction and targeted therapy · 2026Review
- Oral hydrogel systems in lower gastrointestinal disorders: From disease-based therapy to microbiota-guided design.Materials today. Bio · 2026Review
130 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 2 countries.
Funding
Abstract
Colorectal cancer (CRC) is the most common cancer of the digestive system with high mortality and morbidity rates. Gut microbiota is found in the intestines, especially the colorectum, and has structured crosstalk interactions with the host that affect several physiological processes. The gut microbiota include CRC-promoting bacterial species, such as Fusobacterium nucleatum, Escherichia coli, and Bacteroides fragilis, and CRC-protecting bacterial species, such as Clostridium butyricum, Streptococcus thermophilus, and Lacticaseibacillus paracasei, which along with other microorganisms, such as viruses and fungi, play critical roles in the development of CRC. Different bacterial features are identified in patients with early-onset CRC, combined with different patterns between fecal and intratumoral microbiota. The gut microbiota may be beneficial in the diagnosis and treatment of CRC; some bacteria may serve as biomarkers while others as regulators of chemotherapy and immunotherapy. Furthermore, metabolites produced by the gut microbiota play essential roles in the crosstalk with CRC cells. Harmful metabolites include some primary bile acids and short-chain fatty acids, whereas others, including ursodeoxycholic acid and butyrate, are beneficial and impede tumor development and progression. This review focuses on the gut microbiota and its metabolites, and their potential roles in the development, diagnosis, and treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.